MWF

LUBE FOCUS WEEK 2024 Launching in Shanghai this June

Retrieved on: 
Wednesday, February 28, 2024
Carbon, Lubricant, MWF, Exhibition, Council, Zone, Golden Joystick Awards

SHANGHAI, Feb. 28, 2024 /PRNewswire/ -- The 23rd Shanghai International Lubricants and Technology Exhibition (Inter Lubric China), and Shanghai International Metalworking Fluids and Surface Cleaning Technology Exhibition (MWF & SC) will be held from June 5th to 7th, 2024 at Hall E7, Shanghai New International Expo Centre, China.

Key Points: 
  • The Grand Opening of LUBE FOCUS WEEK is taking place from June 3rdto 7th, 2024 in China!
  • SHANGHAI, Feb. 28, 2024 /PRNewswire/ -- The 23rd Shanghai International Lubricants and Technology Exhibition (Inter Lubric China), and Shanghai International Metalworking Fluids and Surface Cleaning Technology Exhibition (MWF & SC) will be held from June 5th to 7th, 2024 at Hall E7, Shanghai New International Expo Centre, China.
  • Hosted by the Council for the Promotion of International Trade Shanghai, and organized by Shanghai Intex Exhibition Co., Ltd., Inter Lubric China, MWF & SC are renowned as authoritative, large-scale, and internationally recognized exhibitions.
  • Welcome to LUBE FOCUS WEEK to facilitate your business connections and collaborations!

C4 Therapeutics Announces Positive Data from CFT7455 Phase 1 Trial in Relapsed/Refractory Multiple Myeloma

Retrieved on: 
Tuesday, December 12, 2023
Well, Patient, CCCC, Leukopenia, Protein, Immunology, Aes, Arm, Completeness, Dexamethasone, Plasma, Anemia, Disease, Neutropenia, Multiple myeloma, Half-life, BCMA, Therapy, Infrared spectroscopy correlation table, SCR, Combination therapy, NHL, MWF, Webcast, Safety, Pharmaceutical industry

C4T also continues to enroll patients in the Phase 1 dose escalation trial exploring CFT7455 as a monotherapy for NHL patients.

Key Points: 
  • C4T also continues to enroll patients in the Phase 1 dose escalation trial exploring CFT7455 as a monotherapy for NHL patients.
  • C4T expects to present the following data on CFT7455 in 2024:
    Complete Phase 1 dose escalation data from the ongoing Phase 1/2 clinical trial in R/R MM.
  • Complete Phase 1 dose escalation data from the ongoing Phase 1/2 clinical trial in NHL.
  • C4T will host an investor webcast today, December 12, 2023, at 4:30 pm Eastern Time, to discuss the CFT7455 Phase 1 clinical data in relapsed/refractory multiple myeloma.

Ligand’s Partner Jazz Pharmaceuticals Receives European Commission Approval for Enrylaze® (a recombinant Erwinia asparaginase or crisantaspase) for the Treatment of Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma

Retrieved on: 
Friday, September 22, 2023
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical Trials, Hypersensitivity, Neutropenia, Contraindication, Maintenance, Lymphocyte, Acute leukemia, Pancreatitis, Febrile neutropenia, IV, Civil service commission, MWF, Diarrhea, ALL, Acute lymphoblastic leukemia, IM, COG, Appetite, Abdominal pain, European Commission, NSAA, Sepsis, LBL, Vomiting, Patient, European, Anemia, Nausea, Headache, EC, Jazz Pharmaceuticals, Thrombocytopenia, Safety, Fatigue, Vaccine, Ligand Pharmaceuticals, Fever

“We congratulate our partner Jazz on its receipt of approval for Enrylaze® from the European Commission, expanding the market opportunity for one of our key commercial-stage products,” said Todd Davis, CEO of Ligand Pharmaceuticals.

Key Points: 
  • “We congratulate our partner Jazz on its receipt of approval for Enrylaze® from the European Commission, expanding the market opportunity for one of our key commercial-stage products,” said Todd Davis, CEO of Ligand Pharmaceuticals.
  • The determination of efficacy was based on demonstration of the achievement and maintenance of nadir serum asparaginase activity (NSAA) levels ≥ 0.1 U/mL.
  • Overall, the safety profile of JZP458 was consistent with the reported safety information for patients with ALL/LBL receiving asparaginase with combination chemotherapy.
  • The European Commission approval extends to all European Union Member states, as well as Iceland, Norway, and Liechtenstein.

7 Mindsets Announces Formation of 7M Cares

Retrieved on: 
Tuesday, March 28, 2023
MWF, Organization, School, Student, Management

ROSWELL, Ga., March 28, 2023 (GLOBE NEWSWIRE) -- 7 Mindsets , the leader in PreK-12 mindsets-based learning and well-being solutions, today announced the formation of 7M Cares, an initiative that will expand the company’s philanthropic impact.

Key Points: 
  • ROSWELL, Ga., March 28, 2023 (GLOBE NEWSWIRE) -- 7 Mindsets , the leader in PreK-12 mindsets-based learning and well-being solutions, today announced the formation of 7M Cares, an initiative that will expand the company’s philanthropic impact.
  • At launch, 7M Cares will exclusively support the Magic Wand Foundation (MWF), an organization co-founded by Scott Shickler and Jeff Waller, co-founders of 7 Mindsets.
  • “The 7M Cares initiative fully embraces the Live to Give Mindset, which teaches us to inspire and serve others,” said Mark Belles, CEO of 7 Mindsets.
  • “The dedicated support from 7M Cares will help transform the number of students we’re able to positively impact,” said Waller.

The Micro Wrestling Federation Announces MICRO PPV1: The Rivalry, Its Inaugural Pay-Per-View Event Airing Feb. 25th at 7PM EST

Retrieved on: 
Tuesday, February 14, 2023
Well, MWF, Blood, Rivalry, Lil, Rolling Stone's 500 Greatest Songs of All Time, Family, Microhistory, Social media, Rock 'n' Roll Express, Livestock

PIGEON FORGE, Tenn., Feb. 14, 2023 /PRNewswire/ -- The Micro Wrestling Federation, which has taken social media by storm, is venturing into the pay-per-view world with its inaugural event, MICRO PPV 1: The Rivalry, airing February 25th at 7PM EST. Fans can order MICRO PPV1: The Rivalry via MicroWrestling.com for $9.99.

Key Points: 
  • PIGEON FORGE, Tenn., Feb. 14, 2023 /PRNewswire/ -- The Micro Wrestling Federation, which has taken social media by storm, is venturing into the pay-per-view world with its inaugural event, MICRO PPV 1: The Rivalry, airing February 25th at 7PM EST.
  • The Rivalry pits the two factions of Micro Wrestling - the road warriors of Micro One and the tourist town entertainers of Micro Too - against each other on an intense six-match card.
  • Other matches include;
    America's Most-Hated Wrestler Flyin' Ryan vs. Micro Hype Man Jamaican Jo
    World-Famous Luchador Micro Tiger vs.
  • The Micro Wrestling Federation, based in Pigeon Forge, Tenn., features 20 cast members under 5-feet-tall, who perform 450-plus professional wrestling shows a year around the United States.

Unifor MWF 1 ratifies agreement with Irving Shipbuilding

Retrieved on: 
Thursday, January 19, 2023
NS, RRSP, Social justice, Mental health, Mid-Atlantic Regional Council on the Ocean (MARCO), Advocate, Woman, Halifax Shipyard, Irving Shipbuilding, Growth, Unifor National Council 4000, Workforce, Race (human categorization), Private sector, MWF, Shipbuilding, Unifor

HALIFAX, NS, Jan. 19, 2023 /CNW/ - Members of Unifor MWF 1 ratified a new four-and-a-half year collective agreement with Irving Shipbuilding.

Key Points: 
  • HALIFAX, NS, Jan. 19, 2023 /CNW/ - Members of Unifor MWF 1 ratified a new four-and-a-half year collective agreement with Irving Shipbuilding.
  • The agreement covers 1,100 skilled trades workers and sees competitive wage increases over the lifetime of the contract.
  • "Unifor members have been instrumental in outreach programs to recruit and remove barriers for women, Black, and Indigenous people to get their trades training and find good jobs at Irving Shipbuilding."
  • Unifor is committed to working with Irving Shipbuilding to successfully deliver vessels as part of The National Shipbuilding Strategy.

Tiziana Life Sciences Ltd (“Tiziana” or “the Company”) - Updated Interim Results for the Six Months Ended 30 June 2022

Retrieved on: 
Thursday, December 29, 2022
MWF, Laboratory, Positron emission tomography, ICH, Disability, MD, GLP, SPMS, BWH, Neurology, Toxicology, Trial of the century, CNS, EAP, Disease, Patient, Immunomodulation, PET, FDA, IND, EDSS, CMSC, EA, Principal, Pharmaceutical industry, Vaccine, Foralumab

LONDON, Dec. 29, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd (“Tiziana”, NASDAQ: TLSA), a biotechnology company enabling breakthrough CNS immunomodulation approaches to enhance the functionality of Treg-based therapies, today announced its interim results for the six months ended 30 June 2022.

Key Points: 
  • LONDON, Dec. 29, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd (“Tiziana”, NASDAQ: TLSA), a biotechnology company enabling breakthrough CNS immunomodulation approaches to enhance the functionality of Treg-based therapies, today announced its interim results for the six months ended 30 June 2022.
  • These protocol amendments or revisions were intended to expedite patient enrollment with study completion targeted for the fourth quarter of 2022.
  • Due to the refocus of the company subsequent to the first six months of 2022, this study has been placed on hold.
  • These results confirm the previously reported data, from the first non-active SPMS patient (EA1) after three months of treatment of intranasal foralumab.

Tiziana Life Sciences Ltd (“Tiziana” or “the Company”) - Interim Results for the Six Months Ended 30 June 2022

Retrieved on: 
Tuesday, December 27, 2022
MWF, White matter, CSO, Calprotectin, ICH, Pharmacokinetics, ADAS, Disability, Board of High School and Intermediate Education Uttar Pradesh, New Drug Application, Thalamus, Principal, GLP, SPMS, Inflammation, BWH, Neurology, Alzheimer's disease, Toxicology, Male, Timed, Trial of the century, Pharmacist, CD, R, Disease, Research, Patient, Cerebellum, Infection, Safety, Expanded Disability Status Scale, PET, FDA, Therapy, IND, EDSS, CMSC, EA, PIND, NSCLC, MD–PhD, Doctor of Philosophy, Pharmaceutical industry, Vaccine, Management, MD, Foralumab

LONDON, Dec. 27, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd (“Tiziana”, NASDAQ: TLSA), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases today announces its interim results for the six months ended 30 June 2022.

Key Points: 
  • LONDON, Dec. 27, 2022 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd (“Tiziana”, NASDAQ: TLSA), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases today announces its interim results for the six months ended 30 June 2022.
  • These protocol amendments or revisions are intended to expedite patient enrollment with study completion targeted for the fourth quarter of 2022.
  • These results confirm the previously reported data, from the first SPMS patient after three months of treatment of the first SPMS patient.
  • For the six months to 30 June 2022 the consolidated Group made a loss of $8.3m (six months to 30 June 2021: $17.0m).

Metalworking Fluids Market Size to Hit $15.1 Billion by 2030: Grand View Research, Inc.

Retrieved on: 
Wednesday, June 8, 2022
Transport, Machine, Growth, Electricity, Mineral, MWF, Industrial, SAN, Application, CAGR, USD, Lithium, Renewable energy

Individual end-use sectors, such as machinery, metal fabrication, and transportation equipment, are driving the expansion of the market.

Key Points: 
  • Individual end-use sectors, such as machinery, metal fabrication, and transportation equipment, are driving the expansion of the market.
  • The machinery segment dominated the market in 2021 due to the high demand for construction equipment and increased infrastructural development activities.
  • Read 108-page market research report, " Metalworking Fluids Market Size, Share & Trends Analysis Report By Product (Mineral, Synthetic), By End-use (Machinery, Transportation Equipment), By Industrial End-use, By Application, And Segment Forecasts, 2022 - 2030 ", published by Grand View Research.
  • Grand View Research has segmented the metalworking fluids market report on the basis of product, application, end-use, industrial end-use, and region:

Tiziana Life Sciences Announces Positive Clinical Results in the Second Patient with Secondary Progressive Multiple Sclerosis (SPMS) Following Three Months of Dosing with Intranasal Foralumab

Retrieved on: 
Wednesday, June 8, 2022
Cerebellum, Encephalitis, Degenerative disease, Immunotherapy, Cone Health Women's Hospital, PET, Company, Mab, IV, Traffic barrier, Harvard Medical School, Food, SPMS, Board of High School and Intermediate Education Uttar Pradesh, Crohn's disease, Positron emission tomography, White matter, Inflammation, Disease, Timed, Lists of diseases, Autoimmunity, FDA, Disability, Male, Massachusetts General Hospital, Patient, Program, GLOBE, Coronavirus Scientific Advisory Board (Turkey), COVID-19, Multiple sclerosis, NEW, MD, Cytokine, Industry, Hospital, Secondary, Neurology, MWF, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, HMS, Nuclear medicine, BWH, Safety, Thalamus, Medical imaging, Pharmaceutical industry, Vaccine, Regulatory T cell, Foralumab, Brigham

These findings are consistent with the results obtained from the first patient following 3-months of treatment, as previously announced on March 10, 2022.

Key Points: 
  • These findings are consistent with the results obtained from the first patient following 3-months of treatment, as previously announced on March 10, 2022.
  • These results confirm the previously reported data, from the first SPMS patient after three months of treatment of the first SPMS patient.
  • The treatment with foralumab, a fully human anti-CD3 monoclonal antibody, was well-tolerated and improved clinical and PET imaging analyses.
  • Both the first and the second patient are continuing with the treatment and are in their 13th and 4th months of treatment, respectively.